Mechanism research of Punicalagin in treating representative strains of enterovirus A and B types based on systems pharmacology and experimental validation

Background: Enteroviruses (EVs), particularly types A (e.g., EV-A71) and B (e.g., CVB3), cause severe complications in vulnerable populations. Limited vaccines and no antivirals underscore the need for broad-spectrum therapies. Punicalagin, a natural anti-inflammatory compound, was investigated for its pan-enteroviral therapeutic potential.

Objective: To evaluate punicalagin's efficacy and mechanisms against multiple EV serotypes via integrated systems pharmacology and experimental validation.

Methods: Network pharmacology identified punicalagin's targets and pathways. In vitro Antiviral activity was assessed in Vero/A549 cells infected with EV-A71/CVB3. Neonatal mice were intraperitoneally inoculated with these viruses to test in vivo efficacy. Molecular docking, Apoptosis assays, and inflammatory factor analyses elucidated mechanisms.

Results: Punicalagin inhibited EV-A71 and CVB3 replication in vitro and improved survival in infected mice. Systems pharmacology linked its effects to anti-apoptotic and anti-inflammatory pathways. Molecular docking confirmed interactions with Apoptosis/inflammation regulators (e.g., CASP3, TNF-α). Experimental validation demonstrated reduced viral-induced Apoptosis and suppressed IL-6/TNF-α levels.

Conclusion: Punicalagin exhibits broad-spectrum anti-enteroviral activity through dual inhibition of Apoptosis and inflammation, validated across in vitro, in vivo, and computational models. This study provides a systems-level framework for repurposing natural compounds against phylogenetically diverse EVs, addressing critical therapeutic gaps for high-risk populations.

Anti-apoptosis; Anti-inflammation; Co-treatment of different diseases; Enterovirus; Punicalagin.